General discussion and future perspectives 227 63. Teunissen FR, Wortel RC, Hes J, Willigenburg T, de Groot-van Breugel EN, de Boer JCJ, et al. Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients. Phys Imaging Radiat Oncol 2021;20:5–10. 64. Teunissen FR, Wortel RC, Wessels FJ, Claes A, van de Pol SMG, Rasing MJA, et al. Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localised prostate cancer. Clin Transl Radiat Oncol 2022;32:29–34. 65. Hehakaya C, van der Voort van Zyp JRN, Vanneste BGL, Grutters JPC, Grobbee DE, Verkooijen HM, et al. Early health economic analysis of 1.5T MRI-guided radiotherapy for localised prostate cancer: Decision analytic modelling. Radiother Oncol 2021;161:74–82. 66. Westley R, Hall E, Tree A. HERMES: Delivery of a Speedy Prostate Cancer Treatment. Clin Oncol (R Coll Radiol) 2022; 34(7):426-429. 67. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, et al. Focal MRI-Guided Salvage High-DoseRate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technol Cancer Res Treat 2017;16:1194–201. 68. van Son M, Monninkhof E, Peters M, Lagendijk J, van der Voort van Zyp J. Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient’s perspective. Clin Transl Radiat Oncol 2020;25:81–7. 69. van Son M, Peters M, Moerland M, van de Pol S, Eppinga W, Lagendijk J, et al. Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients. Clin Transl Radiat Oncol 2021;27:1–7. 70. Jiang P, van der Horst C, Kimmig B, Zinsser F, Poppe B, Luetzen U, et al. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. Brachytherapy 2017;16:186–92. 71. Murgic J, Morton G, Loblaw A, D’Alimonte L, Ravi A, Wronski M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys 2018;102:561–7. 72. Slevin F, Hodgson S, Rodda SL, Bownes P, Bottomley D, Adiotomre E, et al. Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer. Clin Transl Radiat Oncol 2020;23:20–6. 73. Chitmanee P, Tsang Y, Tharmalingam H, Hamada M, Alonzi R, Ostler P, et al. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. Clin Oncol 2020;32:259–65. 74. van Son MJ, Peters M, Moerland MA, Lagendijk JJW, Eppinga WSC, Shah TT, et al. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localised Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. Int J Radiat Oncol 2020;107(1):126-135. 75. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAUEANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263–82. 76. Van Son MJ, Peters M, Moerland MA, Noteboom JL, Eppinga WS, Davila Fajardo R, et al. Re-salvage MRIguided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer. Cureus 2018;10. 77. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1119–34. 78. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355–67. 79. Evans AJ. Treatment effects in prostate cancer. Mod Pathol 2018;31:110–21. 80. Rasing M, van Son M, Moerland M, de Keizer B, Wessels F, Jonges T, et al. Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. Cancers 2022;14. 81. Draulans C, Pos F, Smeenk RJ, Kerkmeijer L, Vogel W V, Nagarajah J, et al. (68)Ga-PSMA-11 PET, (18)F-PSMA1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Pract Radiat Oncol 2021;11:202–11. 82. Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, et al. Validation of different PSMAPET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol 2019;141:208–13. 11
RkJQdWJsaXNoZXIy MTk4NDMw